Introduction
Interference with statural growth in children by corticosteroids is well recognized both in those with Cushing's Senior House Officer, M.R.C. Rheumatism Research Unit, Canadian
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1 Consultant Physician, Canadian Red Cross Hospital, Taplow, Bucks. syndrome (Talbot and Sobel, 1947) and in patients on longterm corticosteroid therapy (Blodgett et al., 1956) . Suppression of the hypothalamic-pituitary-adrenal axis also occurs, and to overcome these problems intermittent corticosteroid or corticotrophin regimens have been advocated (Harter et al., 1963; Soyka, 1967; Friedman and Strang, 1966 
Method
Twenty patients suffering from Still's disease and aged from 7-3 to 15-7 years were studied and divided into four groups (Table I) . Group 1 had never received corticosteroid (Kaplan, 1969) . Plasma cortisol measurements were made by a modification of the competitive protein-binding assay procedure of Murphy et al. (1967) . The procedure was as described by Beardwell et al. (1968) for urine, except that 0-5 to 1 ml. of plasma was extracted with 10 ml. of dichloromethane and 2 ml. of the extract dried down in the assay tube before adding 1 ml. of 2% ethanol in 0-9% saline. The normal range of basal plasma cortisol at 7 a.m. was taken as 5-21 ,ug./100 ml. and the response to insulin hypoglycaemia was considered normal if the maximum plasma cortisol concentration exceeded 20 ,ug./100 ml. (Laron et al., 1969 .Aqe, years . . had suffered from Still's disease for a shorter time than most of those in the other groups. In group 2 those who had received prolonged daily corticosteroid therapy were below the third percentile for height attained, while those currently on the higher dose regimens were on or below the third percentile for height velocity. Conversely shorter periods of treatment and lower doses of prednisone were associated with little or no retardation in height attained and height velocity respectively. In group 3 all three patients showed normal growth, the one who had received alternate-day prednisone from the outset being on the 50th percentile for both height attained and height velocity. In group 4 the patient who had never received corticosteroids was on the 50th percentile for height attained though current height velocity was slow. In contrast the other five who had previously been treated with prolonged daily prednisone were all below the third percentile in height yet their current height velocities showed some recovery of growth.
Growth data for five patients are shown in Figs. 1 and 2. One who had never received corticosteroid therapy and the one who had received only alternate-day prednisone have normal growth while the other three show growth retardation associated with prolonged daily corticosteroid treatment, with recovery of growth in two on discontinuing the drug or changing to an alternate-day corticotrophin regimen.
Basal Studies -Serum Growth Hormone.-Basal growth hormone levels were similar in the four groups (Table II) . All except three patients had mean basal levels below 5 ng./ml., the average being 3*2 ng./ml. The three with higher mean basal levels each had a single level over 10 ng./ml. In each of these patients this single high value was felt to be either not a truly (Table II) . The three in group 3 had normal mean basal plasma cortisol levels, as did five of the six in group 4. Those on alternate-day prednisone had lower plasma cortisol levels at 22 hours after the last dose of prednisone (mean 13-5,ug./100ml.) than at 46 hours (mean 19-7 ,ug./100 ml.). Similarly, patients on alternate-day corticotrophin had lower levels at 22 hours (mean 8 9 ,g./100 ml.) than at 46 hours (mean 11-9 Ag./100 ml.).
Insulin Hypoglycaemia Test
Serum Growth Hormone.-Fasting levels of serum growth hormone on the day of the insulin tolerance test were slightly higher in over half the patients than their mean basal levels (Table II) . Though an adequate hypoglycaemic stimulus was not achieved in two patients, all except one showed a maximum rise in growth hormone at 30 or 60 minutes that was within the normal range (Fig. 3) . In two a subnormal response was obtained in spite of adequate hypoglycaemia, but a repeat test, in one case with a slightly higher dose of insulin (0-15 unit/kg. body weight), resulted in a satisfactory response in both. The one patient who did not respond to hypoglycaemia had an already high basal growth hormone level, as did three others whose responses were in the lower range of normal.
Plasma Cortisols.-At the start of the insulin hypoglycaemia test four of the five in group 1 had fasting plasma cortisol levels higher than their mean basal levels (Table II) whereas in group 2 no difference was noted. The patients in group 3 also showed an increase above their mean basal levels, as did three of the six in group 4. After hypoglycaemic stimulation all patients in group 1 developed a maximum plasma cortisol level over 20 ,ug./100 ml., in spite of inadequate hypoglycaemia in two; but no patient in group 2 showed a normal response to the stimulus (Fig. 4) Linear Growth in Children-Sturge et al. 
Discussion
In common with other chronic disease states, children with Still's disease show generalized growth retardation. This is independent of the local effects, which may result in premature epiphysial fusion and bizarre growth abnormalities, but is dependent on the duration and activity of the illness, only those with prolonged disease developing severe residual height defects (Ansell and Bywaters, 1956 ). Alteration in disease activity and therapy, local effects of disease, and discrepancies between chronological age and bone age make prognostication for final height difficult, but continuous long-term therapy with even moderate doses of corticosteroids results inevitably in further growth suppression. In the present series the two patients treated with alternate-day prednisone or corticotrophin from the outset showed no retardation of growth while those changed from daily prednisone to alternate-day corticotrophin developed at least partial recovery of growth. Patients changed from daily to alternate-day prednisone therany were too few for clear assessment, but it is likely that control of disease activity by any means other than daily corticosteroid administration may allow some recovery of growth.
Basal levels of serum growth hormone were generally lower than those previously reported in children (Friedman and Stimmler, 1966; Morris et al., 1968a; Sanders and Norman, 1969) and similar to those reported in adults (Roth et al., 1963) . It has been suggested that children and adults do not differ in basal secretion of growth hormone (Grumbach, 1966; Glick, 1967) ; and it may be that the precautions we have taken to avoid the effects of stimuli such as exercise and emotion, which can cause a marked increase in growth hormone secretion (Glick et al., 1965; Hunter et al., 1965; Greenwood and Landon, 1966) , have contributed to the low basal levels. Though low basal levels of serum growth hormone have been interpreted as evidence of growth honnone deficiency (Frohman et al., 1967) we feel that the normal growth in at least some of our patients, together with the response to hypoglycaemia, indicates no significant impairment of growth hormone secretion.
Higher basal levels of serum growth hormone were found after cannulation for the insulin tolerance test, possibly owing to the stress of the procedure, and patients with particularly high resting levels showed a reduced response to hypoglycaemia. Similar findings have been recorded by other investigators (Frohman et al., 1967; Stimmler and Brown, 1967; Morris et al., 1968a) and were thought to have no pathological significance. Our findings of a normal growth hormone response to the test stimulus in patients on prolonged low-dosage corticosteroid therapy agree with the findings in two recent series of asthmatic children treated with long-term continuous steroids (Morris et al., 1968a; Sanders and Norman. 1969) . The difference between these and previous studies (Frantz and Rabkin, 1964; Hartog et al., 1964) probably lies in the higher doses of steroids given to adults by the earlier investigators, though children also have shown some impairment of growth hormone release when given daily prednisone in doses of 7-5 mg. and above (Friedman and Greenwood, 1968) . The results in our two patients who had repeat tests agree with the contention that a negative growth hormone response to a single adequate test stimulus does not permit a diagnosis of growth hormone deficiency (Raiti et al., 1967; Martin et al., 1968) .
It is of interest that recent workers (Morris et al.. 1968b) (Blodgett et al., 1956) or changing from a daily to an alternate-day regimen with either prednisone (Soyka, 1967) or corticotrophin (Friedman and Strang, 1966) . Recovery does not always occur, and some patients appear to have a persistent retardation of growth . Fasting plasma cortisol levels before insulin hypoglycaemia were higher in some patients than their mean basal levels and probably represent a response to the stress of cannulation similar to that seen with-growth hormone. Little further increase in plasma cortisol in response to hypoglycaemia in patients with already high basal levels has been reported (Bacon et al., 1968; Laron et al., 1969) and does not necessarily indicate a poor response to the test. Our patients treated without corticosteroids were within the normal range for basal cortisol secretion and response to hypoglycaemia, whereas those on daily corticosteroid therapy had low levels of plasma cortisol, except for one on a very low dose of prednisone, and none showed a normal response to hypoglycaemia.
Low basal levels of plasma cortisol in patients on corticosteroid therapy must be interpreted with caution as they may represent an effect of the previous day's steroid dose rather than chronic suppression of the hypothalamic-pituitaryadrenal axis. This could explain levels lower at 22 hours than at 46 hours in the patients on alternate-day prednisone, but those levels were within the normal range and indicate no significant impairment of basal cortisol secretion. Their response to hypoglycaemia was also normal. Other workers have reported variable impairment of circadian rhythm or response to hypoglycaemia in patients on alternate-day prednisone (Ackerman and Nolan, 1968; Jasani et al., 1968; Sadeghi-Nejad and Senior, 1969) and the dose of prednisone used is probably the critical factor in determining which patients will be affected.
The lower basal levels of plasma cortisol observed in the corticotrophin-treated patients 22 hours after injection of corticotrophin compared with those at 46 hours may at first seem anomalous, but the explanation probably also lies in the effect of the injection on the circadian rhythm of cortisol secretion. The declining levels of plasma cortisol in the evening after the injection will probably be sufficiently above the normal basal level to cause at least partial suppression of the following day's intrinsic rhythm, as has been described for physiological amounts of administered corticosteroid (Nichols et al.. 1965) , with return to the normal circadian rhythm during the second 24 hours. Apart from one patient, however, these patients also showed no significant impairment of basal cortisol secretion, though in those previously treated with long-term corticosteroids the response to hypoglycaemia was subnormal. It may be significant that a normal response to hypoglycaemia was seen in the patient who had never received corticosteroids and in the one who had previously received daily corticosteroid plus intermittent corticotrophin before changing to corticotrophin alone.
Lack of suppression of the hypothalamic-pituitary-adrenal axis by daily corticvtrophin has been reported in adults (Bacon et al., 1968; Carter and James, 1970) and children (Friedman and Greenwood, 1968) , but this may not be invariable (Wynn, 1968) . Alternate-day therapy with corticotrophin is presumably even less likely to cause suppression but it appears that full return of hypothalamic-pituitary-adrenal function after changing from long-term corticosteroid to alternate-day corticotrophin does not necessarily occur. We can offer no satisfactory explanation for this when compared with return of normal function in adults who had previously received corticosteroid therapy (Carter and James, 1970) , but it is possible that differences in dose and duration of therapy account for the findings in our patients.
